Crizotinib, an ALK tyrosine kinase inhibitor, was approved in 2011, after clinical trials showed superior efficacy with overall response and progression-free survival when compared with the standard NSCLC chemotherapy regimen (Gerber, Ghandi, & Costa, 2014). The gene discussed is ALK; the disease is non-small cell lung carcinoma.